Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts

Cell Death and Disease

Volumn 2, Issue 2, 2011, Pages

  Liu, Y ^a   Lang, F ^a   Xie, X ^a,b   Prabhu, S ^a   Xu, J ^a   Sampath, D ^a   Aldape, K ^a   Fuller, G ^a   Puduvalli, V K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adenovirus; Apoptosis; Glioma; Organotypic slice cultures; Soluble TRAIL

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT; ADENOVIRUS; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; FEMALE; FROZEN SECTION; GENE THERAPY; GENE VECTOR; GENETICS; INSTRUMENTATION; METABOLISM; NUDE MOUSE; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ADENOVIRIDAE; RODENTIA;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FROZEN SECTIONS; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 79959965210     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2010.95     Document Type: Article

References (28)

1. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-12690. (Pubitemid 26175834)
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682. (Pubitemid 26091143)
3. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113. (Pubitemid 27161256)
4. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996; 6: 750-752. (Pubitemid 126656342)
5. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-260. (Pubitemid 29164042)
6. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002; 21: 2283-2294. (Pubitemid 34407288)
7. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277: 815-818. (Pubitemid 27366732)
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308. (Pubitemid 28406815)
9. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567. (Pubitemid 30305907)
10. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U et al. Human braincell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356: 827-828.
11. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385.
12. Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics. Adv Exp Med Biol 2009; 647: 195-206.
13. Naumann U, Waltereit R, Schulz JB, Weller M. Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. J Neurooncol 2003; 61: 7-15. (Pubitemid 36187638)
14. Roth W, Isenmann S, Naumann U, Kugler S, Bahr M, Dichgans J et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. Biochem Biophys Res Commun 1999; 265: 479-483.
15. Kagawa S, He C, Gu J, Koch P, Rha SJ, Roth JA et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001; 61: 3330-3338. (Pubitemid 32695022)
16. Lal S, Lacroix M, Tofilon P, Fuller GN, Sawaya R, Lang FF. An implantable guide-screw system for brain tumor studies in small animals. J Neurosurg 2000; 92: 326-333. (Pubitemid 30071053)
17. Daza RAM, Englund C, Hevner RF. Organotypic slice culture of embryonic brain tissue. Cold Spring Harb Protoc 2007; doi:10.1101/pdb.prot4914.
18. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-194. (Pubitemid 40826487)
19. Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008; 26: 3621-3630.
20. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000; 165: 2886-2894. (Pubitemid 30660741)
21. Kim KU, Seo SY, Heo KY, Yoo YH, Kim HJ, Lee HS et al. Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells. J Korean Med Sci 2005; 20: 1046-1052.
22. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
23. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005; 10: 233-243. (Pubitemid 40558131)
24. Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP et al. Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther 2006; 13: 330-338. (Pubitemid 43223102)
25. Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW et al. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One 2009; 4: e4545.
26. Soria J-C, Smit E, Khayat D, Besse B, Yang X, Hsu C-P et al. Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in combination with Paclitaxel, Carboplatin, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol 2010; 28: 1527-1533.
27. Lin T, Gu J, Zhang L, Huang X, Stephens LC, Curley SA et al. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002; 62: 3620-3625. (Pubitemid 34728835)
28. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombination. J Virol 1997; 71: 1842-1849. (Pubitemid 27078561)